Zacks Research Estimates Avantor’s Q1 Earnings (NYSE:AVTR)

Avantor, Inc. (NYSE:AVTR) – Research analysts at Zacks Research lowered their Q1 2026 earnings per share estimates for Avantor in a research note issued to investors on Tuesday, December 10th. Zacks Research analyst D. Dey now expects that the company will post earnings per share of $0.30 for the quarter, down from their previous estimate of $0.32. The consensus estimate for Avantor’s current full-year earnings is $0.98 per share. Zacks Research also issued estimates for Avantor’s Q3 2026 earnings at $0.31 EPS and FY2026 earnings at $1.26 EPS.

AVTR has been the subject of a number of other research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $34.00 target price on shares of Avantor in a research report on Thursday, September 26th. Wells Fargo & Company lowered their target price on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. Robert W. Baird cut their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Barclays reduced their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Finally, UBS Group cut their price target on shares of Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, October 8th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $27.69.

Avantor Price Performance

Shares of AVTR stock opened at $22.33 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. Avantor has a twelve month low of $19.59 and a twelve month high of $28.00. The firm has a fifty day simple moving average of $22.53 and a 200-day simple moving average of $23.54. The company has a market capitalization of $15.20 billion, a PE ratio of 48.98, a price-to-earnings-growth ratio of 2.75 and a beta of 1.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AVTR. Blue Trust Inc. boosted its stake in Avantor by 1,830.3% in the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after purchasing an additional 1,391 shares during the period. UMB Bank n.a. bought a new stake in shares of Avantor in the 3rd quarter valued at approximately $49,000. Nisa Investment Advisors LLC boosted its stake in Avantor by 69.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after buying an additional 835 shares during the period. GAMMA Investing LLC grew its holdings in Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after purchasing an additional 1,285 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt increased its stake in Avantor by 278.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock worth $130,000 after purchasing an additional 3,700 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.